{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:43:40Z","timestamp":1793040220269,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fondazione Cassa di Risparmio di Bologna, Bando \u201cRicerca medica e alta tecnologia\u201d 2021","id":[{"id":"https:\/\/ror.org\/00t3rz591","id-type":"ROR","asserted-by":"crossref"}]},{"name":"\"Ricerca Corrente\" funding from the Italian Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00216-026-06669-x","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:55:05Z","timestamp":1784915705000},"page":"6455-6469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma LC-HRMS metabolomics in parkinsonian syndromes: comparative evaluation of sample preparation protocols for exploratory metabolic signatures"],"prefix":"10.1007","volume":"418","author":[{"given":"Erika","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lopane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Interino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Caravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cancellerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Calandra-Buonaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-5118","authenticated-orcid":false,"given":"Jessica","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Contin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"6669_CR1","doi-asserted-by":"publisher","unstructured":"Chen CJ, Lee DY, Yu J, Lin YN, Lin TM. Recent advances in LC-MS-based metabolomics for clinical biomarker discovery. Mass Spectrom Rev. Wiley. 2023;42(6):2349\u20132378. https:\/\/doi.org\/10.1002\/mas.21785.","DOI":"10.1002\/mas.21785"},{"key":"6669_CR2","doi-asserted-by":"publisher","unstructured":"Castelli FA, Rosati G, Moguet C, et al. Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests.  https:\/\/doi.org\/10.1007\/s00216-021-03586-z\/Published.","DOI":"10.1007\/s00216-021-03586-z\/Published"},{"key":"6669_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237579","author":"A Mehta","year":"2020","unstructured":"Mehta A, Liu C, Nayak A, et al. Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0237579.","journal-title":"PLoS ONE"},{"key":"6669_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260354","author":"E Lebeau-Roche","year":"2021","unstructured":"Lebeau-Roche E, Daniele G, Fildier A, et al. An optimized LC-HRMS untargeted metabolomics workflow for multi-matrices investigations in the three-spined stickleback. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0260354.","journal-title":"PLoS ONE"},{"issue":"10","key":"6669_CR5","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1021\/jasms.3c00158","volume":"34","author":"H Safari Yazd","year":"2023","unstructured":"Safari Yazd H, Bazargani SF, Fitzpatrick G, Yost RA, Kresak J, Garrett TJ. Metabolomic and lipidomic characterization of meningioma grades using LC-HRMS and machine learning. J Am Soc Mass Spectrom. 2023;34(10):2187\u201398. https:\/\/doi.org\/10.1021\/jasms.3c00158.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"4","key":"6669_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.molcel.2015.04.021","volume":"58","author":"N Zamboni","year":"2015","unstructured":"Zamboni N, Saghatelian A, Patti GJ. Defining the Metabolome: Size, Flux, and Regulation. Mol Cell Cell Press. 2015;58(4):699\u2013706. https:\/\/doi.org\/10.1016\/j.molcel.2015.04.021.","journal-title":"Mol Cell Cell Press"},{"key":"6669_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Mol Cell Biol. 2016;17:451\u20139. https:\/\/doi.org\/10.1038\/nrm.2016.25.","journal-title":"Mol Cell Biol."},{"issue":"12","key":"6669_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13361-016-1469-y","volume":"27","author":"AC Schrimpe-Rutledge","year":"2016","unstructured":"Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted metabolomics strategies\u2014challenges and emerging directions. J Am Soc Mass Spectrom. 2016;27(12):1897\u2013905. https:\/\/doi.org\/10.1007\/s13361-016-1469-y.","journal-title":"J Am Soc Mass Spectrom"},{"key":"6669_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114930","author":"HW Liao","year":"2022","unstructured":"Liao HW, Cheng YW, Tang SC, Kuo CH. Bias caused by incomplete metabolite extraction and matrix effect: evaluation of critical factors for plasma sample preparation prior to metabolomics. J Pharm Biomed Anal. 2022. https:\/\/doi.org\/10.1016\/j.jpba.2022.114930.","journal-title":"J Pharm Biomed Anal"},{"issue":"20","key":"6669_CR10","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1039\/d0an01319f","volume":"145","author":"AD Southam","year":"2020","unstructured":"Southam AD, Haglington LD, Najdekr L, Jankevics A, Weber RJM, Dunn WB. Assessment of human plasma and urine sample preparation for reproducible and high-throughput UHPLC-MS clinical metabolic phenotyping. Analyst. 2020;145(20):6511\u201323. https:\/\/doi.org\/10.1039\/d0an01319f.","journal-title":"Analyst"},{"key":"6669_CR11","doi-asserted-by":"publisher","unstructured":"Buszewska-Forajta M, Raczak-Gutknecht J, Struck-Lewicka W, et al. Untargeted metabolomics study of three matrices: seminal fluid, urine, and serum to search the potential indicators of prostate cancer. Front Mol Biosci. 2022;9.  https:\/\/doi.org\/10.3389\/fmolb.2022.849966.","DOI":"10.3389\/fmolb.2022.849966"},{"key":"6669_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082580","author":"G Frigerio","year":"2022","unstructured":"Frigerio G, Moruzzi C, Mercadante R, Schymanski EL, Fustinoni S. Development and application of an LC-MS\/MS untargeted exposomics method with a separated pooled quality control strategy. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27082580.","journal-title":"Molecules"},{"issue":"29","key":"6669_CR13","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1007\/s00216-014-8212-y","volume":"406","author":"E Rico","year":"2014","unstructured":"Rico E, Gonz\u00e1lez O, Blanco ME, Alonso RM. Evaluation of human plasma sample preparation protocols for untargeted metabolic profiles analyzed by UHPLC-ESI-TOF-MS. Anal Bioanal Chem. 2014;406(29):7641\u201352. https:\/\/doi.org\/10.1007\/s00216-014-8212-y.","journal-title":"Anal Bioanal Chem"},{"key":"6669_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/srep38885","volume":"6","author":"DG Sitnikov","year":"2016","unstructured":"Sitnikov DG, Monnin CS, Vuckovic D. Systematic Assessment of Seven Solvent and Solid-Phase Extraction Methods for Metabolomics Analysis of Human Plasma by LC-MS. Sci Rep. 2016;6:6. https:\/\/doi.org\/10.1038\/srep38885.","journal-title":"Sci Rep."},{"key":"6669_CR15","doi-asserted-by":"publisher","unstructured":"Vuckovic D. Sample preparation in global metabolomics of biological fluids and tissues. In: Proteomic and metabolomic approaches to biomarker discovery. Elsevier; 2019. p. 53\u201383. https:\/\/doi.org\/10.1016\/B978-0-12-818607-7.00004-9.","DOI":"10.1016\/B978-0-12-818607-7.00004-9"},{"issue":"2","key":"6669_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1021\/acs.analchem.1c03638","volume":"94","author":"J Chaker","year":"2022","unstructured":"Chaker J, Kristensen DM, Halldorsson TI, et al. Comprehensive evaluation of blood plasma and serum sample preparations for HRMS-based chemical exposomics: overlaps and specificities. Anal Chem. 2022;94(2):866\u201374. https:\/\/doi.org\/10.1021\/acs.analchem.1c03638.","journal-title":"Anal Chem"},{"issue":"21","key":"6669_CR17","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1002\/rcm.4264","volume":"23","author":"J Smalley","year":"2009","unstructured":"Smalley J, Xin B, Olah TV. Increasing high-throughput discovery bioanalysis using automated selected reaction monitoring compound optimization, ultra-high-pressure liquid chromatography, and single-step sample preparation workflows. Rapid Commun Mass Spectrom. 2009;23(21):3457\u201364. https:\/\/doi.org\/10.1002\/rcm.4264.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"3","key":"6669_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","volume":"3","author":"LW Sumner","year":"2007","unstructured":"Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007;3(3):211\u201321. https:\/\/doi.org\/10.1007\/s11306-007-0082-2.","journal-title":"Metabolomics"},{"key":"6669_CR19","doi-asserted-by":"publisher","unstructured":"Alonso A, Marsal S, Juli\u00e0 A. Analytical methods in untargeted metabolomics: State of the art in 2015. Front Bioeng Biotechnol.  2015;3(MAR).https:\/\/doi.org\/10.3389\/fbioe.2015.00023. Frontiers Media S.A.","DOI":"10.3389\/fbioe.2015.00023"},{"key":"6669_CR20","doi-asserted-by":"publisher","unstructured":"Hajnajafi K, Iqbal MA. Mass-spectrometry based metabolomics: an overview of workflows, strategies, data analysis and applications. Proteome Sci. BioMed Central Ltd. 2025;23(1). https:\/\/doi.org\/10.1186\/s12953-025-00241-8.","DOI":"10.1186\/s12953-025-00241-8"},{"key":"6669_CR21","doi-asserted-by":"publisher","unstructured":"Lin C, Tian Q, Guo S, et al. Metabolomics for clinical biomarker discovery and therapeutic target identification. Molecules. 2024;29(10).  https:\/\/doi.org\/10.3390\/molecules29102198. Multidisciplinary Digital Publishing Institute (MDPI).","DOI":"10.3390\/molecules29102198"},{"issue":"7","key":"6669_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT. Parkinson\u2019s Disease and Parkinsonism. American Journal of Medicine. 2019;132(7):802\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.001. Elsevier Inc.","journal-title":"American Journal of Medicine."},{"issue":"1","key":"6669_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1): 17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13.","journal-title":"Nat Rev Dis Primers"},{"key":"6669_CR24","doi-asserted-by":"publisher","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson\u2019s Syndrome. 2022. https:\/\/doi.org\/10.1146\/annurev-pathmechdis.","DOI":"10.1146\/annurev-pathmechdis"},{"issue":"9","key":"6669_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrn1199","volume":"4","author":"E Maries","year":"2003","unstructured":"Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of \u03b1-synuclein in Parkinson\u2019s disease: insights from animal models. Nat Rev Neurosci. 2003;4(9):727\u201338. https:\/\/doi.org\/10.1038\/nrn1199.","journal-title":"Nat Rev Neurosci"},{"key":"6669_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ibneur.2024.04.008","volume":"16","author":"E Ichikawa-Escamilla","year":"2024","unstructured":"Ichikawa-Escamilla E, Velasco-Mart\u00ednez RA, Adalid-Peralta L. Progressive supranuclear palsy syndrome: an overview. IBRO Neurosci Rep. 2024;16:598\u2013608. https:\/\/doi.org\/10.1016\/j.ibneur.2024.04.008. Elsevier B.V.","journal-title":"IBRO Neurosci Rep"},{"issue":"4","key":"6669_CR27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40120-024-00614-9","volume":"13","author":"EE Dunning","year":"2024","unstructured":"Dunning EE, Decourt B, Zawia NH, Shill HA, Sabbagh MN. Pharmacotherapies for the treatment of progressive supranuclear palsy: a narrative review. Neurol Ther Adis. 2024;13(4):975\u20131013. https:\/\/doi.org\/10.1007\/s40120-024-00614-9.","journal-title":"Neurol Ther Adis"},{"key":"6669_CR28","doi-asserted-by":"publisher","unstructured":"Mori A, Ishikawa KI, Saiki S, et al. Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. PLoS One. 2019;14(9).  https:\/\/doi.org\/10.1371\/journal.pone.0223113.","DOI":"10.1371\/journal.pone.0223113"},{"issue":"6","key":"6669_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00702-016-1545-2","volume":"123","author":"KA Jellinger","year":"2016","unstructured":"Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and biomarkers. J Neural Transm Springer-Verlag Wien. 2016;123(6):555\u201372. https:\/\/doi.org\/10.1007\/s00702-016-1545-2.","journal-title":"J Neural Transm Springer-Verlag Wien"},{"issue":"5","key":"6669_CR30","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1007\/s00415-024-12269-5","volume":"271","author":"M Liu","year":"2024","unstructured":"Liu M, Wang Z, Shang H. Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. J Neurol. 2024;271(5):2324\u201344. https:\/\/doi.org\/10.1007\/s00415-024-12269-5. Springer Science and Business Media Deutschland GmbH.","journal-title":"J Neurol."},{"key":"6669_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","volume":"73","author":"DG Coughlin","year":"2020","unstructured":"Coughlin DG, Litvan I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020;73:105\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.04.014.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"6669_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3238\/arztebl.2016.0061","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU. \u00dcBERSICHTSARBEIT: Differenzialdiagnose und Therapie der atypischen Parkinson-Syndrome. Dtsch Arztebl Int. 2016;113(5):61\u20139. https:\/\/doi.org\/10.3238\/arztebl.2016.0061.","journal-title":"Dtsch Arztebl Int"},{"key":"6669_CR33","doi-asserted-by":"publisher","unstructured":"Papathoma PE, Markaki I, Tang C, et al. A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Sci Rep. 2022;12(1).  https:\/\/doi.org\/10.1038\/s41598-022-06663-0.","DOI":"10.1038\/s41598-022-06663-0"},{"issue":"12","key":"6669_CR34","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"issue":"9","key":"6669_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15.","journal-title":"Neurology"},{"issue":"6","key":"6669_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"key":"6669_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30452","author":"LA Dahabiyeh","year":"2024","unstructured":"Dahabiyeh LA, Nimer RM, Wells JD, Abu-rish EY, Fiehn O. Diagnosing Parkinson\u2019s disease and monitoring its progression: biomarkers from combined GC-TOF MS and LC-MS\/MS untargeted metabolomics. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30452.","journal-title":"Heliyon"},{"key":"6669_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00694-5","author":"KC Paul","year":"2023","unstructured":"Paul KC, Zhang K, Walker DI, et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson\u2019s disease. Mol Neurodegener. 2023. https:\/\/doi.org\/10.1186\/s13024-023-00694-5.","journal-title":"Mol Neurodegener"},{"key":"6669_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11120860","author":"M Pathan","year":"2021","unstructured":"Pathan M, Wu J, Lakso H\u00c5, Forsgren L, \u00d6hman A. Plasma metabolite markers of Parkinson\u2019s disease and atypical parkinsonism. Metabolites. 2021. https:\/\/doi.org\/10.3390\/metabo11120860.","journal-title":"Metabolites"},{"key":"6669_CR40","doi-asserted-by":"publisher","unstructured":"Luo X, Liu Y, Balck A, Klein C, Fleming RMT. Identification of metabolites reproducibly associated with Parkinson\u2019s Disease via meta-analysis and computational modelling. NPJ Parkinsons Dis. 2024;10(1).  https:\/\/doi.org\/10.1038\/s41531-024-00732-z.","DOI":"10.1038\/s41531-024-00732-z"},{"key":"6669_CR41","doi-asserted-by":"publisher","unstructured":"Shima S, Mizutani Y, Yoshimoto J, et al. Uric acid and alterations of purine recycling disorders in Parkinson\u2019s disease: a cross-sectional study. NPJ Parkinsons Dis. 2024;10(1).  https:\/\/doi.org\/10.1038\/s41531-024-00785-0.","DOI":"10.1038\/s41531-024-00785-0"},{"key":"6669_CR42","doi-asserted-by":"publisher","unstructured":"Saiki S, Hatano T, Fujimaki M, et al. Decreased long-chain acylcarnitines from insufficient \u03b2-oxidation as potential early diagnostic markers for Parkinson\u2019s disease. Sci Rep. 2017;7(1).  https:\/\/doi.org\/10.1038\/s41598-017-06767-y.","DOI":"10.1038\/s41598-017-06767-y"},{"key":"6669_CR43","doi-asserted-by":"publisher","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18(1). https:\/\/doi.org\/10.1186\/s13024-023-00676-7. BioMed Central Ltd.","DOI":"10.1186\/s13024-023-00676-7"},{"key":"6669_CR44","doi-asserted-by":"publisher","unstructured":"Tripodi G, Lombardo M, Kerav S, Aiello G, Baldelli S. Nitric oxide in Parkinson\u2019s disease: the potential role of dietary nitrate in enhancing cognitive and motor health via the nitrate\u2013nitrite\u2013nitric oxide pathway. Nutrients. 2025;17(3).  https:\/\/doi.org\/10.3390\/nu17030393. Multidisciplinary Digital Publishing Institute (MDPI).","DOI":"10.3390\/nu17030393"},{"issue":"12","key":"6669_CR45","doi-asserted-by":"publisher","first-page":"8294","DOI":"10.1002\/alz.14249","volume":"20","author":"R Batra","year":"2024","unstructured":"Batra R, Krumsiek J, Wang X, et al. Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer\u2019s disease and progressive supranuclear palsy. Alzheimers Dement. 2024;20(12):8294\u2013307. https:\/\/doi.org\/10.1002\/alz.14249.","journal-title":"Alzheimers Dement"},{"key":"6669_CR46","doi-asserted-by":"publisher","unstructured":"D\u2019Ascenzo N, Antonecchia E, Angiolillo A, et al. Metabolomics of blood reveals age-dependent pathways in Parkinson\u2019s Disease. Cell Biosci. 2022;12(1).  https:\/\/doi.org\/10.1186\/s13578-022-00831-5.","DOI":"10.1186\/s13578-022-00831-5"},{"issue":"2","key":"6669_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell Elsevier BV. 2023;186(2):243\u201378. https:\/\/doi.org\/10.1016\/j.cell.2022.11.001.","journal-title":"Cell Elsevier BV"},{"key":"6669_CR48","doi-asserted-by":"publisher","unstructured":"Yang L, Shen J, Liu C, et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun. 2023;14(1).  https:\/\/doi.org\/10.1038\/s41467-023-36543-8.","DOI":"10.1038\/s41467-023-36543-8"},{"key":"6669_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-0185-5","author":"S Kaji","year":"2020","unstructured":"Kaji S, Maki T, Ishimoto T, Yamakado H, Takahashi R. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions. Transl Neurodegener. 2020. https:\/\/doi.org\/10.1186\/s40035-020-0185-5.","journal-title":"Transl Neurodegener"},{"key":"6669_CR50","doi-asserted-by":"publisher","unstructured":"Wan L, Zhu S, Chen Z, Qiu R, Tang B, Jiang H. Multidimensional biomarkers for multiple system atrophy: an update and future directions. Transl Neurodegener. BioMed Central Ltd. 2023;12(1).  https:\/\/doi.org\/10.1186\/s40035-023-00370-00.","DOI":"10.1186\/s40035-023-00370-00"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-026-06669-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00216-026-06669-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-026-06669-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:09:26Z","timestamp":1789625366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00216-026-06669-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["6669"],"URL":"https:\/\/doi.org\/10.1007\/s00216-026-06669-x","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the authors\u2019 Institutional Review Board (No. 843\u20132021-SPER-AUSLBO Comitato Etico Indipendente dell\u2019Area Vasta Emilia Centro, CE AVEC). Written informed consent was obtained from each subject.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The biological material consisted of human plasma samples from clinically defined PD, MSA-P, and PSP-P patients, collected under the approved study protocol as described in the Methods.","order":2,"name":"Ethics","label":"Source of biological material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}